It's official: dramatic share price jumps in response to clinical data have become more common.
Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
Alkermes manages to shrug off yesterday’s complete response letter, but US knockbacks in 2020 are creeping up.
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
Venture-backed companies are floating earlier, but time to takeout stays stubbornly steady.
An analysis of FDA complete response letters does not reveal a big uptick – but the year is not over yet.
Welcome to the calm before the Covid-19 storm.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.